3.1.2. 60+ Age Cohort
neutropenia, anemia
MASSIVE BLOOD LOSS, SARS-COV-2 INFECTION, NEUTROPENIA, ANEMIA, AGRANULOCYTOSIS
The study profile in the 60+ age cohort is presented in In total, out of 200 participants that passed screening, 32 were excluded during the study: 16 (8%) had confirmed SARS-CoV-2 infection, 9 (4.5%) contracted other ARIs, 1 (0.5%) was in quarantine after contact with a person with confirmed COVID-19, 2 (1%) did not come to scheduled visits, 1 (0.5%) received drugs that were prohibited by the study protocol, and 2 (1%) withdrew consent. One participant was excluded on the day of the 1st vaccination before vaccine administration, as he had a medical history of massive blood loss, anemia (hemoglobin below 80 g/L), agranulocytosis, and neutropenia (below 1000 neutrophils per microliter) that was not detected at screening.Thus, out of 200 participants who were initially included, 199 (99.5%) received the first dose of the vaccine, 175 (87.5%) received the second dose and entered immunogenicity assessment after two doses, and 168 (84%) received the third dose and entered immunogenicity assessment after three doses according to the protocol.